Literature DB >> 24466543

Attempts to treat patients with hemophilia, the "royal disease".

Rojin Park1.   

Abstract

Entities:  

Year:  2013        PMID： 24466543      PMCID： PMC3894377          DOI： 10.5045/br.2013.48.4.235

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  10 in total

1.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

2.  The Presence of a Circulating Anti-Coagulant in a Male Member of a Hemophiliac Family.

Authors:  J S Lawrence; J B Johnson
Journal:  Trans Am Clin Climatol Assoc       Date:  1941

3.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Authors:  Jan Astermark; Sharyne M Donfield; Donna M DiMichele; Alessandro Gringeri; Steven A Gilbert; Jennifer Waters; Erik Berntorp
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

Review 4.  Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.

Authors:  Jørgen Ingerslev; Benny Sørensen
Journal:  Br J Haematol       Date:  2011-09-07       Impact factor: 6.998

5.  Getting rid of refractory hemophilia.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood       Date:  2012-02-09       Impact factor: 22.113

Review 6.  How we treat a hemophilia A patient with a factor VIII inhibitor.

Authors:  Christine L Kempton; Gilbert C White
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

7.  Pharmaco-economic aspects of inhibitor treatment.

Authors:  J Goudemand
Journal:  Eur J Haematol Suppl       Date:  1998

Review 8.  Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.

Authors:  E Berntorp
Journal:  Haemophilia       Date:  2008-11-10       Impact factor: 4.287

9.  The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

Authors:  S C Darby; D M Keeling; R J D Spooner; S Wan Kan; P L F Giangrande; P W Collins; F G H Hill; C R M Hay
Journal:  J Thromb Haemost       Date:  2004-07       Impact factor: 5.824

10.  Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.

Authors:  Myung Hee Han; Young Shil Park
Journal:  Blood Res       Date:  2013-12-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.